MSD\'s Keytruda boosts overall survival by 31 in advanced oesophageal cancer

MSD's Keytruda boosts overall survival by 31% in advanced oesophageal cancer

05:54 EST 16 Jan 2019 | Pharmafile

MSD has unveiled new Phase 3 data for its blockbuster anti-PD-1 immunotherapy Keytruda (pembrolizumab), showing that the drug succeeded in hitting its primary endpoint of improving overall survival (OS) as a monotherapy in the second-line treatment of of advanced or metastatic esophageal or esophagogastric junction carcinoma.

The company said that the results represented the first time that an anti-PD-1 therapy has shown a survival benefit in this patient population.

read more

More From BioPortfolio on "MSD's Keytruda boosts overall survival by 31% in advanced oesophageal cancer"